COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04313023

Colin Broom, MD

clinicaltrials@pulmotect.com

2020-03-18

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

inclusion criteria: subjects must have recent exposure to sars-cov-2 (such as repeated or extensive exposure to an infected individual(s) or cohabiting with a sars-cov-2 positive individual). subjects must be 50 years or older if the exposure is due to cohabitation. subjects must be free of clinical signs or symptoms of a potential covid-19 diagnosis (ordinal scale of clinical improvement score of 0) with a sars-cov-2 infection symptom score (fever, cough, shortness of breath, and fatigue) of 0 in each category. spirometry (forced expiratory volume in one second fev1 and forced vital capacity [fvc]) ≥70% of predicted value. if female, the subject must be surgically sterile or ≥ 1 year postmenopausal. if of child-bearing potential (including being < 1years postmenopausal) and, if participating in sexual activity that may lead to pregnancy, the subject agrees to use an effective dual method of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study. if female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. a pregnancy test must be negative at the screening visit, prior to dosing on day 1. if male, must be surgically sterile or, if not surgically sterile and if participating in sexual activities that may lead to pregnancy, be willing to practice two effective methods of birth control (acceptable methods include barrier, spermicide, or female partner surgical sterilization) during the study and through 30 days after completion of the study. ability to understand and give informed consent.

previous infection with sars-cov-2. receipt of any vaccine for the prevention of covid-19 (single or multiple doses). a sars-cov-2 infection symptom score greater than 0 in any of the 4 catergories (fever, cough, shortness of breath or fatigue) at the time of screening (ordinal scale for clinical improvement score of 0). known history of chronic pulmonary disease (e.g., asthma [including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection], chronic pulmonary disease, pulmonary fibrosis, copd), pulmonary hypertension, or heart failure. any condition which, in the opinion of the principal investigator, would prevent full participation

2

Pulmotect, Inc.

18

None

United States

Close contacts to covid patients

N/A

217

Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of Experimental Therapy.

None

Phase 2

[{"arm_notes": "", "treatment_id": 1041, "treatment_name": "Pul-042 inhalation solution", "treatment_type": "Respiratory agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]